President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine

President Trump has signed an executive order to fast-track psychedelic research and FDA approval, sparking debate among doctors over safety and mental health benefits.

US President ⁠Donald Trump on Saturday announced ​reforms intended to speed up ‌access to medical ‌research and treatment ⁠based ⁠on psychedelic drugs. Trump planned to sign an ​executive order that would direct the U.

President Donald Trump on Saturday signed an executive order aimed at expanding research into a psychedelic drug called ibogaine - an effort Texas has joined. The move to ease restrictions into researching the drug are part of a broader push for scientists to study the therapeutic benefits of LSD,

President Trump signed an executive order Saturday that eases restrictions on the research of the psychedelics including the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder.

President Trump signed an executive order to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and conservative lawmakers despite having serious safety risks.

The president issued an executive order increasing research into drugs used to treat PTSD and other disorders.

The executive order signed by President Donald Trump aims to accelerate research into psychedelic drugs to help veterans.